C3G

Clinical trials for C3G explained in plain language.

Never miss a new study

Get alerted when new C3G trials appear

Sign up with your email to follow new studies for C3G, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet finished but already full! 1 Completed 1 Terminated 1

New hope for rare kidney disease patients through early access program

Disease control APPROVED_FOR_MARKETING

This program provides early access to an investigational drug called pegcetacoplan for patients with rare kidney diseases C3G or IC-MPGN. It's for people aged 12+ who haven't responded well to other treatments and have active kidney disease. Participants must be able to self-admi…

Matched conditions: C3G

Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 23, 2026 15:17 UTC

C3G

Get alerted when new C3G trials appear

New hope for rare kidney disease patients through early access program